ClinicalTrials.gg

Program

botulinum toxin type A

Also written as “Botulinum toxin type A”, “Botulinum Toxin Type A” and “botulinum toxin Type A”.

In AbbVie’s pipeline, SNAP-25. Its studies are mostly in Torticollis · Urinary Bladder, Overactive · Migraine Disorders · Muscle Spasticity · Stroke, led by 27 companies.

Furthest: phase 4, since Sep 13, 2005285 company-led studies, 13 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie814 open or runningphase 4since Sep 13, 2005Jan 29, 2004Jun 2027phase 4 · NCT07794891
Ipsen442 open or runningphase 4since Sep 13, 2005Aug 23, 2005none ahead
Merz Pharma425 open or runningphase 4since Oct 8, 2007Nov 30, 2006Mar 2027phase 3 · NCT07018700
Medy-Tox240 open or runningphase 4since Nov 25, 2010Nov 4, 2010none ahead
Revance190 open or runningphase 3since Jan 18, 2013Aug 27, 2009none ahead
Galderma Group150 open or runningphase 4since Mar 5, 2014Nov 16, 2009none ahead
GlaxoSmithKline100 open or runningphase 3since Dec 6, 2006Dec 6, 2006none ahead
Hugel101 open or runningphase 4since Aug 19, 2018Feb 5, 2013none ahead
anterios-inc50 open or runningphase 2since Feb 9, 2011Feb 9, 2011none ahead
Daewoong Pharmaceutical50 open or runningphase 3since Sep 16, 2013Sep 16, 2013none ahead
Eirion Therapeutics50 open or runningphase 2since Oct 27, 2017Oct 27, 2017none ahead
Croma-Pharma30 open or runningphase 3since Oct 22, 2015Oct 22, 2015none ahead
Johnson & Johnson30 open or runningphase 3since Sep 10, 2008Sep 10, 2008none ahead
Sinopharm30 open or runningphase 3since Oct 29, 2014Oct 29, 2014none ahead
edigene-guangzhou-inc20 open or runningphase 1since Jun 4, 2021Jun 4, 2021none ahead
evolus-inc20 open or runningphase 3since Jan 6, 2015Jan 6, 2015none ahead
li-nguyen20 open or runningphase 2since Feb 26, 2014Feb 26, 2014none ahead
asis-corporation10 open or runningphase 2since Feb 26, 2014Feb 26, 2014none ahead
atgc-co-ltd10 open or runningphase 2since Feb 20, 2020Feb 20, 2020none ahead
Azidus Brasil10 open or runningphase 3since Aug 10, 2010Aug 10, 2010none ahead
biolab-sanus-farmaceutica10 open or runningphase 3since Sep 29, 2009Sep 29, 2009none ahead
espad-pharmed10 open or runningphase 3since Apr 19, 2025Apr 19, 2025none ahead
Huons Global11 open or runningphase 3since Jul 18, 2023Jul 18, 2023none ahead
inibio-co-ltd10 open or runningphase 3since May 26, 2026May 26, 2026none ahead
LEO Pharma10 open or runningphase 1since Oct 9, 2015Oct 9, 2015none ahead
pacific-pharmaceuticals10 open or runningphase 3since May 20, 2008May 20, 2008none ahead
rmw-testing10 open or runningphase 2since Aug 4, 2023Aug 4, 2023none ahead
  • Named in AbbVie’s own pipeline as GemibotulinumtoxinA, phase 2, as of Jul 30, 2026 (source).

Also a collaborator on its studies: PPD DEVELOPMENT, LP, Laboratório Químico Farmacêutico Bergamo Ltda., Synteract and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Mar 29, 2019.

  1. Aug 4, 2023rmw-testing’s first study: phase 2 study in Pulmonary Disease, Chronic ObstructiveNew to rmw-testingrmw-testing · NCT06003049 · 40 enrolled · United States
  2. Sep 14, 20232 phase 3 studiesIpsen · NCT06047457, NCT06047444
  3. Oct 13, 2023Phase 2 study in Neuralgia, PostherpeticMerz Pharma · NCT06091020 · 123 enrolled · Bulgaria, France, Germany and more
  4. Jan 15, 2025Phase 4 study in Facial ContouringAbbVie · NCT06783621 · 130 enrolled · United States
  5. Jan 21, 2025Phase 3 study in Forehead LinesAbbVie · NCT06794866 · 150 enrolled · Japan
  6. Apr 19, 2025espad-pharmed’s first study: phase 3 study in Glabellar LinesNew to espad-pharmedespad-pharmed · NCT06946160 · 146 enrolled · Iran, Islamic Republic of
  7. Jun 4, 20252 phase 3 studiesMerz Pharma · NCT07018713, NCT07018700
  8. Aug 7, 2025Phase 3 study in Neuromuscular AgentsMerz Pharma · NCT07122193 · 300 enrolled · United States, Puerto Rico
  9. Sep 29, 2025Phase 3 study in Neuromuscular AgentsMerz Pharma · NCT07210463 · 300 enrolled · France, Germany, Poland and more
  10. Nov 7, 2025Phase 2 study in Hernia, VentralAbbVie · NCT07226791 · 200 planned · United States
  11. May 26, 2026inibio-co-ltd’s first study: phase 3 study in Glabellar LinesNew to inibio-co-ltdinibio-co-ltd · NCT07622004 · 292 enrolled · South Korea
  12. Jun 23, 2026Phase 2 study in Upper Limb Essential TremorAbbVie · NCT07673107 · 94 planned · United States, Canada
  13. Aug 27, 2026Phase 4 study in Jawline and Neck AppearanceAbbVie · NCT07794891 · 100 planned · Canada
  14. Oct 7, 2026Phase 2 study in Upper Facial LinesAbbVie · NCT07871513 · 300 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 3 study in Chronic MigraineMerz Pharma · NCT07018713
  2. Mar 2027Primary completion: phase 3 study in Episodic MigraineMerz Pharma · NCT07018700
  3. Jun 2027Primary completion: phase 4 study in Jawline and Neck AppearanceAbbVie · NCT07794891
  4. Jun 2028Primary completion: phase 2 study in Upper Facial LinesAbbVie · NCT07871513

TargetBeta

“SNAP-25”the company's pipeline, read by Claude · source
“Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme”ChEMBL 37, by rule

Other programs on SNAP25

ProgramCompanyFurthest phaseStudies
trenibotulinumtoxinEruleAbbViephase 311
prabotulinumtoxin Aruleaeon-biopharma-incphase 39

Studies

The newest 60 of 285 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07871513Upper Facial Lines · United States2RecruitingAbbVieJun 2028300
NCT07794891Jawline and Neck Appearance · Canada4RecruitingAbbVieJun 2027100
NCT07673107Upper Limb Essential Tremor · United States, Canada2RecruitingAbbVieNov 202894
NCT07622004Glabellar Lines · South Korea3Completedinibio-co-ltdJan 30, 2022292
NCT07226791Hernia, Ventral · United States2RecruitingAbbVieSep 2028200
NCT07210463Neuromuscular Agents · France, Germany, Poland and more3Active, not recruitingMerz PharmaAug 5, 2026300
NCT07122193Neuromuscular Agents · United States, Puerto Rico3Active, not recruitingMerz PharmaJun 5, 2026300
NCT07018713Chronic Migraine · United States, Austria, Canada and more3Active, not recruitingMerz PharmaMar 2027808
NCT07018700Episodic Migraine · United States, Austria, Canada and more3Active, not recruitingMerz PharmaMar 2027997
NCT06946160Glabellar Lines · Iran, Islamic Republic of3Completedespad-pharmedFeb 18, 2025146
NCT06794866Forehead Lines · Japan3CompletedAbbVieApr 3, 2026150
NCT06783621Facial Contouring · United States4CompletedAbbVieMar 20, 2026130
NCT06091020Neuralgia, Postherpetic · Bulgaria, France, Germany and more2CompletedMerz PharmaMay 7, 2025123
NCT06047457Episodic Migraine · United States, Canada, Czechia and more3Active, not recruitingIpsenJun 1, 2026751
NCT06047444Chronic Migraine · United States, Canada, Czechia and more3Active, not recruitingIpsenMay 28, 2026759
NCT06003049Pulmonary Disease, Chronic Obstructive · United States2Completedrmw-testingApr 24, 202440
NCT05964257Benign Masseteric Hypertrophy · Korea, Republic of3Active, not recruitingHuons GlobalMar 7, 2024188
NCT05956509Muscle Spasticity · United States1TerminatedAbbVieJun 2, 20241
NCT05801146Glabellar Lines · Korea, Republic of3RecruitingHugelMar 2025272
NCT05784363Enlarged Pores · United States1CompletedMerz PharmaJun 17, 202431
NCT05773053Platysma Prominence · United States2CompletedMerz PharmaOct 19, 202373
NCT05752123Transfusion Dependent Beta-Thalassaemia · China–Terminatededigene-guangzhou-incJan 29, 20242
NCT05606757Hernia, Ventral · United States2WithdrawnAbbVieApr 22, 20250
NCT05585398N/A, as no Specific Medical Condition Will be Treated · Germany1CompletedMerz PharmaFeb 24, 202340
NCT05463965Moderate to Severe Glabellar Lines · China3CompletedGalderma GroupJan 29, 2023605
NCT05217355Glabellar Frown Lines · Korea, Republic of2CompletedMedy-ToxJun 22, 202250
NCT05152576Forehead Lines · United States2CompletedAbbVieSep 6, 2022124
NCT05134649Platysma Prominence · United States, Canada3CompletedAbbVieAug 18, 2023292
NCT05148000Glabellar Frown Lines · United States3CompletedGalderma GroupMar 31, 202325
NCT05146999Glabellar Frown Lines · United States3CompletedGalderma GroupOct 28, 2022132
NCT05100199Glabellar Lines · United States2CompletedAbbVieDec 2, 2022328
NCT05013424Glabellar Lines · United States2CompletedAbbVieJul 7, 202292
NCT04994535Platysma Prominence · United States, Belgium, Canada and more3CompletedAbbVieJun 14, 2023426
NCT04985916Lateral Canthal Lines, LCL · United States2CompletedEirion TherapeuticsFeb 8, 2024280
NCT04970407Healthy Participants · United Kingdom1CompletedIpsenMar 16, 202245
NCT04949399Platysma Prominence · United States, Canada3CompletedAbbVieDec 20, 2022408
NCT04944953Glabellar Lines · Korea, Republic of1CompletedHugelSep 2, 202138
NCT04936542Upper Limb Spasticity · United States, Canada, France and more4CompletedIpsenAug 26, 2025464
NCT04925206beta-Thalassemia · China1Terminatededigene-guangzhou-incJan 30, 20248
NCT04766723Essential Tremor of the Upper Limb · United States, Canada, Poland2CompletedMerz PharmaApr 26, 202378
NCT04622254Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) · Germany3CompletedMerz PharmaJun 16, 2021368
NCT04594213Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) · United States3CompletedMerz PharmaApr 15, 2021362
NCT04443244Benign Masseteric Hypertrophy · Korea, Republic of2CompletedHugelNov 18, 202080
NCT04281095Glabellar Frown Lines · Korea, Republic of2Completedatgc-co-ltdApr 30, 202060
NCT04281745Glabellar Frown Lines · Korea, Republic of4UNKNOWNMedy-ToxJun 17, 2020200
NCT04247074Glabellar Frown Lines (GL) · United States, Canada3CompletedGalderma GroupOct 2, 2020413
NCT04225260Glabellar Lines · United States, Puerto Rico3CompletedGalderma GroupApr 12, 2021902
NCT04259086Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) · United States, Canada2CompletedRevanceNov 2, 202048
NCT04186442Urinary Bladder, Overactive · Korea, Republic of1CompletedHugelApr 26, 202138
NCT04143854Lateral Canthal Lines · Australia2CompletedMedy-ToxAug 19, 2020150
NCT04143815Glabellar Frown Lines · Australia2CompletedMedy-ToxSep 1, 2020200
NCT04080882Platysmal Bands · United States2CompletedGalderma GroupDec 30, 201980
NCT04073303Masseter Muscle Prominence · Canada, China, Taiwan3CompletedAbbVieNov 10, 2022377
NCT04113941Urinary Bladder, Overactive · Korea, Republic of3UNKNOWNMedy-ToxApr 15, 2020216
NCT04171258Torticollis · Korea, Republic of1CompletedHugelApr 26, 202138
NCT03992404Brain Injuries, Traumatic · United States, Belgium, Canada and more3Active, not recruitingMerz PharmaJun 19, 2025603
NCT03985982Glabellar Frown Lines · United States3CompletedCroma-PharmaDec 4, 2019410
NCT03960957Glabellar Frown Lines · United States3CompletedGalderma GroupSep 27, 2019301
NCT03912805Lateral Canthal Lines, LCL · United States2CompletedEirion TherapeuticsMay 6, 201938
NCT03915067Platysma Prominence · United States, Canada2CompletedAbbVieApr 16, 2020171

How it is read

Names in the registry

  • “Botulinum toxin type A”, 69 entries
  • “Botulinum Toxin Type A”, 28 entries
  • “botulinum toxin Type A”, 21 entries
  • “OnabotulinumtoxinA”, 15 entries
  • “NT 201”, 13 entries

Codes read as this program: ET01, GSK1358820.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.